AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24300198 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 734
Study 19915784 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-keyworker relationship
Number of subjects: 312
Study 19915784 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-vocational worker relationship (rated by client)
Number of subjects: 312
Study 19915784 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational worker-rated relationship
Number of subjects: 312
Study 19915784 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-keyworker and client-vocational worker relationships
Number of subjects: 312
Study 18959451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier-Activated Lullaby (PAL)
Number of subjects: 60
Study 18959451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier-Only
Number of subjects: 60
Study 18959451 — intervention group
Group type: COMPARATOR
Intervention: No-Contact
Number of subjects: 60
Study 16039496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 82
Study 16039496 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 82
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 25 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 75 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 150 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 300 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 500 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF 4000 microg
Number of subjects: 50
Study 12525720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10847254 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy with INR > 6.0
Number of subjects: 114
Study 10847254 — intervention group
Group type: EXPERIMENTAL
Intervention: INR > 6.0
Number of subjects: 114
Study 10847254 — intervention group
Group type: COMPARATOR
Intervention: INR in target range (2.0 to 3.0)
Number of subjects: 114
Study 8664133 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 160 mg day‐1
Number of subjects: 122
Study 8664133 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 320 mg day‐1
Number of subjects: 122
Study 8664133 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 320 mg day‐1 (further therapy)
Number of subjects: 122
Study 8664133 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) at 480 mg day‐1 (further therapy)
Number of subjects: 122
Study 1514886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 46
Study 1514886 — intervention group
Group type: COMPARATOR
Intervention: Sterile intermittent catheterization
Number of subjects: 46
Study 6740497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-estrogen therapy (tamoxifen, Nolvadex) added to chemotherapy (cyclophosphamide, methotrexate, and fluorouracil - CMF)
Number of subjects: 312
Study 6740497 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific immunotherapy with bacillus Calmette-Guerin
Number of subjects: 312
Study 29969366 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ALL treatment
Number of subjects: 39
Study 29969366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 29604548 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative Er:YAG laser therapy
Number of subjects: 114
Study 29604548 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 114
Study 26759000 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-based prednisolone (BW)
Number of subjects: 100
Study 26759000 — intervention group
Group type: COMPARATOR
Intervention: Body surface area-based prednisolone (BSA)
Number of subjects: 100
Study 25304789 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic powder containing Lactobacillus reuteri 10(8) CFU and 4.3 g of soluble fiber
Number of subjects: 20
Study 25304789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22505658 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy (S + RT)
Number of subjects: 0
Study 22505658 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study 19828469 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured feedback provided by an experienced supervisor
Number of subjects: 22
Study 19828469 — intervention group
Group type: COMPARATOR
Intervention: Non-feedback group (control)
Number of subjects: 22
Study 19828469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 17852417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during E2-only withdrawal
Number of subjects: 26
Study 17852417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) during withdrawal from E2 + P
Number of subjects: 26
Study 16199359 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-led tutorials (SLT)
Number of subjects: 91
Study 16199359 — intervention group
Group type: COMPARATOR
Intervention: Faculty-led tutorials (FLT)
Number of subjects: 91
Study 12084370 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 106
Study 12084370 — intervention group
Group type: COMPARATOR
Intervention: Short Individual Intervention (SII)
Number of subjects: 106
Study 9524981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 86
Study 9524981 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 86
Study 7714935 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (nalidixic acid)
Number of subjects: 33
Study 7714935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffective antimicrobial therapy
Number of subjects: 33
Study 7714935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features and laboratory tests
Number of subjects: 33
Study 2665385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mictonorm (45 mg/d)
Number of subjects: 46
Study 2665385 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasuret (300 mg/d)
Number of subjects: 46
Study 2665385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 20917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (10 mg)
Number of subjects: 6
Study 20917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 6
Study 20917 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflubazam (20 mg)
Number of subjects: 6
Study 20917 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflubazam (40 mg)
Number of subjects: 6
Study 20917 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 6
Study 31982072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 307
Study 31982072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 307
Study 31982072 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 307
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Care-seeking behavior
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age of child (infants compared with children)
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Caretaker with primary education compared with none
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine awareness
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding awareness
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fever
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of tachypnea
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chest indrawing
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of persistent vomiting
Number of subjects: 1152
Study 31482784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of recurrent illness
Number of subjects: 1152
Study 28418269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow centralizer
Number of subjects: 60
Study 28418269 — intervention group
Group type: COMPARATOR
Intervention: Solid centralizer
Number of subjects: 60
Study 28418269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25995301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracyclines
Number of subjects: 816
Study 25995301 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 816
Study 25995301 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous It-TIL
Number of subjects: 816
Study 25995301 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Str-TIL
Number of subjects: 816
Study 23375815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source CT with a pitch of 3.0 and bolus triggering at 140 HU with a delay of 10s (group 2)
Number of subjects: 160
Study 23375815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch CT angiography (group 2, 3, and 4)
Number of subjects: 160
Study 23375815 — intervention group
Group type: COMPARATOR
Intervention: Conventional single-source CT with a pitch of 1.2 (group 1)
Number of subjects: 160
Study 21334221 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) training using the wave form of 20 Hz exponential pulse from the 2nd post‐operative day to 4 weeks after the surgery.
Number of subjects: 20
Study 21334221 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation program (Control group).
Number of subjects: 20
Study 19135906 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visitation services (n=236)
Number of subjects: 501
Study 19135906 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=265)
Number of subjects: 501
Study 19135906 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visitation services for mothers exposed at gestational age of <=24 weeks
Number of subjects: 501
Study 17570424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg QD)
Number of subjects: 850
Study 17570424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 15155304 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation (PENS) for 8 weeks (Group A)
Number of subjects: 53
Study 15155304 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation (PENS) for 4 weeks followed by transcutaneous electrical nerve stimulation (TENS) for 4 weeks (Group B)
Number of subjects: 53
Study 15155304 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 8 weeks (Group C)
Number of subjects: 53
Study 11448394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive paper tape (PT group)
Number of subjects: 300
Study 11448394 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture (IS group)
Number of subjects: 300
Study 9079242 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (250 mg flutamide)
Number of subjects: 20
Study 9079242 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (250 mg flutamide)
Number of subjects: 20
Study 8485068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg bid for 4 weeks
Number of subjects: 101
Study 8485068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg bid for 4 weeks (if needed)
Number of subjects: 101
Study 8485068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg bid)
Number of subjects: 101
Study 8485068 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 101
Study 2875003 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS) 30 mg/kg intravenous (maximum dose 3 g)
Number of subjects: 1118
Study 2875003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1118
Study 2875003 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1118
Study 31660983 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-DANTE-SPACE
Number of subjects: 38
Study 31660983 — intervention group
Group type: COMPARATOR
Intervention: DANTE-SPACE
Number of subjects: 38
Study 31660983 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-DANTE-SPACE and DANTE-SPACE
Number of subjects: 38
Study 28067979 — intervention group
Group type: EXPERIMENTAL
Intervention: D.T. Light-Post-removal kit
Number of subjects: 45
Study 28067979 — intervention group
Group type: EXPERIMENTAL
Intervention: Start-X stainless-steel ultrasonic tips
Number of subjects: 45
Study 28067979 — intervention group
Group type: COMPARATOR
Intervention: Control group (fiber posts left without removal)
Number of subjects: 45
Study 27797095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided superficial/combined cervical plexus block
Number of subjects: 98
Study 27797095 — intervention group
Group type: COMPARATOR
Intervention: Infiltration anaesthesia
Number of subjects: 98
Study 24658627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 32 mg
Number of subjects: 52
Study 24658627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24658627 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 52
Study 22789455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention
Number of subjects: 268
Study 22789455 — intervention group
Group type: COMPARATOR
Intervention: Wellness Contact Control
Number of subjects: 268
Study 20075789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE) with tri-iodothyronine +/- methylprednisolone therapy
Number of subjects: 66
Study 20075789 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial echocardiography
Number of subjects: 66
Study 20075789 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat echocardiography
Number of subjects: 66
Study 20075789 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-guided management
Number of subjects: 66
Study 20075789 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid status and hormonal therapy
Number of subjects: 66
Study 18341818 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI combined percutaneous thrombectomy group
Number of subjects: 56
Study 18341818 — intervention group
Group type: COMPARATOR
Intervention: PCI group
Number of subjects: 56
Study 15725970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 12
Study 15725970 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 12
Study 14685056 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 monotherapy
Number of subjects: 12
Study 14685056 — intervention group
Group type: COMPARATOR
Intervention: Five-drug regimen (zidovudine, lamivudine, abacavir, indinavir, nevirapine)
Number of subjects: 12
Study 10590488 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided antiarrhythmic drug therapy
Number of subjects: 0
Study 10590488 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0
Study 8851370 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS fentanyl (Duragesic, TTS‐F)
Number of subjects: 39
Study 1308377 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA occluded with Orahesive Oral Bandages
Number of subjects: 20
Study 1308377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6589647 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene 200 mg/d
Number of subjects: 18
Study 6589647 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg/d
Number of subjects: 18
Study 6589647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 750 mg/d
Number of subjects: 18
Study 3539032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled and oral salbutamol
Number of subjects: 56
Study 3539032 — intervention group
Group type: COMPARATOR
Intervention: Inhaled dry powder of salbutamol
Number of subjects: 56
Study 30953835 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 20
Study 30953835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27816366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 90
Study 27816366 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg)
Number of subjects: 90
Study 26571889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (massage therapy + magnetic sticking therapy at auricular points)
Number of subjects: 72
Study 26571889 — intervention group
Group type: COMPARATOR
Intervention: Simple massage therapy
Number of subjects: 72
Study 23127919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (one dose)
Number of subjects: 59
Study 23127919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (two doses)
Number of subjects: 59
Study 23127919 — intervention group
Group type: EXPERIMENTAL
Intervention: MLV vaccine
Number of subjects: 59
Study 23127919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 23127919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated virus vaccine (one or two doses)
Number of subjects: 59
Study 21558878 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (40 mg/d + 10 mg/d)
Number of subjects: 46
Study 21558878 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin + Placebo (40 mg/d + placebo)
Number of subjects: 46
Study 18295624 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation (ES) during cycling training
Number of subjects: 12
Study 18295624 — intervention group
Group type: COMPARATOR
Intervention: Cycling training without electric stimulation (control)
Number of subjects: 12
Study 16579803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5000 or 10,000 iu daily)
Number of subjects: 700
Study 16579803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 12548041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine stress 99mTc tetrofosmin (DSTF) quantitative gated SPECT
Number of subjects: 24
Study 11508317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11508317 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 100 mg bid
Number of subjects: 40
Study 11508317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium Polynicotinate (Cr) 200 microg bid
Number of subjects: 40
Study 11508317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cr and GSE (200 microg Cr and 100 mg GSE bid)
Number of subjects: 40
Study 9124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion
Number of subjects: 7
Study 9124549 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (5% dextrose in water)
Number of subjects: 7
Study 9124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg)
Number of subjects: 7
Study 9124549 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP infusion after lisinopril
Number of subjects: 7
Study 1326902 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-hydroxybutyric acid (50 mg/kg/day, divided into three daily doses)
Number of subjects: 82
Study 1326902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 1326902 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-hydroxybutyric acid
Number of subjects: 82
Study 3921173 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 3921173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31975413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 mcg/kg bwt
Number of subjects: 99
Study 31975413 — intervention group
Group type: COMPARATOR
Intervention: Romifidine 20 mcg/kg bwt
Number of subjects: 99
Study 30879447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic height planning
Number of subjects: 200
Study 30879447 — intervention group
Group type: COMPARATOR
Intervention: Conventional templating
Number of subjects: 200
Study 27803216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual mobility acetabular component
Number of subjects: 20
Study 27803216 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene component
Number of subjects: 20
Study 24831977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799
Study 24831977 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799
Study 24831977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 799
Study 24831977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study 22511399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 96
Study 22511399 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 20464778 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-powered nebulized albuterol
Number of subjects: 42
Study 20464778 — intervention group
Group type: COMPARATOR
Intervention: Air/oxygen-powered nebulized albuterol (placebo)
Number of subjects: 42
Study 18824462 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin monotherapy
Number of subjects: 0